by The global KRAS inhibitors market size was valued at USD 102.36 million in 2022 and is projected to reach USD 165.63 million by 2032, growing at a CAGR of 4.93% from 2023 to 2032, According to Precedence Research.
q
The global KRAS inhibitors market boons an in-depth synopsis of the competitive landscape of the market globally, thus helping establishments understand the primary threats and prospects that players/vendors in the market are dealt with. It also incorporates thorough business profiles of some of the prime vendors in the market.
Download The Sample Copy For Better Understanding@ https://www.precedenceresearch.com/sample/3035
KRAS Inhibitors Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 107.41 Million |
| Market Size by 2032 | USD 165.63 Million |
| Growth Rate from 2023 to 2032 | CAGR of 4.93% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Cancer Type and By End-Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: Hydrogen Infrastructure Market Size, Share, Outlook 2032
Benefits of this market
- This study analyses the market size and share for KRAS inhibitors along with the present trends in the industry and forecasts for the future, showing investment opportunities for the future.
- In order to compare the financial capabilities of the KRAS inhibitors market in the present, a quantitative analysis is done of the market from 2023 to 2032.
- It is clear from this brilliant presentation of Porter’s Five Forces that buyers and suppliers have a lot of potential to gain from one another.
- It is important to understand the most profitable trends in the KRAS inhibitors market in order to gain an advantage in the market.
- A comprehensive analysis of the driving factors, limitations, and opportunities is provided in the report, along with an in-depth analysis of the effect they have on the market.
- The report also includes the market share for KRAS inhibitors for several significant vendors as well as the latest developments in the market.
Leading players of the global KRAS inhibitors market are analysed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. Precedence Research provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global KRAS inhibitors market. Furthermore, the report offers two separate market forecasts – one for the production side and another for the consumption side of the global KRAS inhibitors market. It also provides useful recommendations for new as well as established players of the global KRAS inhibitors market.
The major players in the market
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics, Inc.
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology, Inc.
KRAS Inhibitors Market Segmentations:
By Cancer Type
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
By End-Use
- Clinic Laboratories
- Cancer Diagnostic Centers
- Hospitals
- Cancer Research Institutes
- Academic Institutions
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on KRAS Inhibitors Market
5.1. COVID-19 Landscape: KRAS Inhibitors Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global KRAS Inhibitors Market, By Cancer Type
8.1. KRAS Inhibitors Market Revenue and Volume, by Cancer Type, 2023-2032
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Pancreatic Cancer
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global KRAS Inhibitors Market, By End-Use
9.1. KRAS Inhibitors Market Revenue and Volume, by End-Use, 2023-2032
9.1.1. Clinic Laboratories
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Cancer Diagnostic Centers
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Hospitals
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Cancer Research Institutes
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
9.1.5. Academic Institutions
9.1.5.1. Market Revenue and Volume Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global KRAS Inhibitors Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.1.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.1.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.1.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.2.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.2.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.2.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.2.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.2.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.3.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.3.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.3.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.3.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.4.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.4.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.4.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.4.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.5.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)
10.5.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)
Chapter 11. Company Profiles
11.1. Amgen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boehringer Ingelheim
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. BridgeBio Pharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Erasca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Innovent Biologics, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Incyte
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Mirati Therapeutics
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Novartis
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Jemincare
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Cardiff Oncology, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Key inquiries addressed in the report:
- Investigate the COVID 19 outbreak’s effects.
- Our researchers give precise responses, pinpoint significant chances and fresh investments, and suggest excellent market strategy avenues.
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
